Background: Cerebral venous thromboses (CVT) with distinct clinical presentations have been shown worldwide. However, there is little information regarding race-ethnic differences in this disease. Methods: We prospectively studied 50 CVT patients from Brazil, comparing clinical and laboratory data among white (W) and African-Brazilian (AB) patients. Results: Seventy percent of the patients were female, 26 W and 23 AB, mean age 34.7 years. Multiple sinus CVT, deep CVT and worse outcome were significantly more frequent in AB than in W patients. There was a trend towards a higher frequency of factor V Leiden and prothrombin mutation in W than in AB, and of protein C deficiency in AB. Conclusions: CVT was more severe in AB patients than in W patients. Race-ethnic differences may account for the heterogeneous distribution of inherited thrombophilia in this series.

1.
Bousser MG, Chiras J, Bories J, Castaigne P: Cerebral venous thrombosis – A review of 38 cases. Stroke 1985;16:199–213.
2.
Ameri A, Bousser MG: Cerebral venous thrombosis. Neurol Clin 1992;10:87–111.
3.
Cantú C, Barinagarrementeria F: Cerebral venous thrombosis associated with pregnancy and puerperium. Review of 67 cases. Stroke 1993;24:1880–1884.
4.
Daif A, Awada A, Al-Rajeh S, Abduljabbar M, Al Tahan AR, Obeid T, Malibary T: Cerebral venous thrombosis in adults. A study of 40 cases from Saudi Arabia. Stroke 1995;26:1193–1195.
5.
Ferro JM, Correia M, Pontes C, Baptista MV, Pita F: Cerebral vein and dural sinus thrombosis in Portugal: 1980–1998. Cerebrovasc Dis 2001;11:177–182.
6.
Ridker PM, Miletich JP, Hennekens CH, Buring JE: Ethnic distribution of factor V Leiden in 4,047 men and women. Implications for venous thromboembolism screening. JAMA 1997;277:1305–1307.
7.
Rees DC, Cox M, Clegg JB: World distribution of factor V Leiden. Lancet 1995;346:1133–1134.
8.
Bousser MG, Russell RR: Cerebral venous thrombosis; in Warlow CP, van Gijn J (eds): Major Problems in Neurology, ed 1. London, WB Saunders, 1997, pp 88–133.
9.
Wilson WA, Gharavi A, Koike T, Lockshin MD, Branch DW, Piette JC, Brey R, Derksen R, Harris EN, Hughes GRV, Triplett DA, Khamashta MA: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999;42:1309–1311.
10.
Sacco RL, Boden-Albala B, Abel G, Lin IF, Elkind M, Hauser WA, Paik MC, Shea S: Race-ethnic differences in the impact of stroke risk factors: The northern Manhattan stroke study. Stroke 2001;32:1725–1731.
11.
Pickle LW, Mungiole M, Gillum RF: Geographic variation in stroke mortality in blacks and whites in the United States. Stroke 1997;28:1639–1647.
12.
Lanska DJ, Kryscio RJ: Risk factors for peripartum and postpartum stroke and intracranial venous thrombosis. Stroke 2000;31:1274–1282.
13.
Weih M, Vetter B, Castell S, Ziemer S, Kulozik AE, Einhäulp KM: Hereditary thrombophilia in cerebral venous thrombosis. Cerebrovasc Dis 2000;10:161–162.
14.
Jerrard-Dunne P, Evans A, McGovern R, Hajat C, Kalra L, Rudd AG, Wolfe CD, Markus HS: Ethnic differences in markers of thrombophilia: Implications for the investigation of ischemic stroke in multiethnic populations: The South London Ethnicity and Stroke Study. Stroke 2003;34:1821–1826.
15.
Kearon C, Crowther M, Hirsh J: Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 2000;51:169–185.
16.
Jones MR, Horner RD, Edwards LJ, Hoff J, Armstrong SB, Smith-Hammond CA, Matchar DB, Oddone EZ: Racial variation in initial stroke severity. Stroke 2000;31:563–567.
17.
Stolz E, Gerriets T, Bödeker RH, Hügens-Penzel M, Kaps M: Intracranial venous hemodynamics is a factor related to a favorable outcome in cerebral venous thrombosis. Stroke 2002;33:1645–1650.
18.
Kapral MK, Wang H, Mamdani M, Tu JV: Effect of socioeconomic status on treatment and mortality after stroke. Stroke 2002;33:268–275.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.